, the average time from submission to first decision for all original research papers submitted to Circulation Research was 11.94 days.
I n 3 randomized controlled trials (RCTs), therapies that inhibit CETP (cholesteryl ester transfer protein) have failed to demonstrate a reduction in risk for coronary heart disease (CHD). [1] [2] [3] Possible reasons for this failure include ontarget lack of efficacy, off-target adverse effects of the small molecule, and RCT design factors, such as insufficient statistical power, concurrent statin therapy, or selection of study
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Novelty and Significance
What Is Known?
• Human DNA sequence variants that truncate a therapeutic target protein may provide insight into the efficacy of pharmacological inhibition.
• It has been uncertain whether carriers of protein-truncating variants (PTVs) at the cholesteryl ester transfer protein (CETP) gene have altered plasma lipid levels and lower risk for coronary heart disease (CHD).
What New Information Does This Article Contribute?
• Carriers of a PTV at CETP had higher high-density lipoprotein cholesterol, lower low-density lipoprotein cholesterol, and lower triglycerides.
• CETP PTV carrier status was also associated with 30% reduced risk for CHD.
• Lifelong reduction in CETP function is associated with altered plasma lipids and a lower risk for CHD.
Therapies that inhibit CETP have failed to demonstrate a reduction in risk for CHD. Human DNA sequence variants that truncate a therapeutic target gene may provide insight into the efficacy of pharmacological inhibition. We tested whether humans carrying PTVs at the CETP gene were associated with lipid levels and were at reduced risk for CHD. We sequenced the exons of the CETP gene in 58 469 participants from 12 case-control and genotyped 1 Japanese-specific PTV in 27 561 participants from 3 case-control studies. PTVs at the CETP gene were defined as mutations that lead to a premature stop, disrupt canonical splice sites, or lead to insertions/deletions that shift frame. In an analysis including >80 000 participants, carriers of a PTV at CETP had higher high-density lipoprotein cholesterol (+22.6 mg/dL), lower low-density lipoprotein cholesterol (−12.2 mg/dL), and lower triglycerides (−6.3%). CETP PTV carrier status was also associated with 30% reduced risk for CHD (summary odds ratio, 0.70).
In conclusion, compared with noncarriers, carriers of PTV at the CETP gene displayed higher high-density lipoprotein cholesterol, lower low-density lipoprotei cholesterol, lower triglycerides, and lower risk for CHD.
participants. [4] [5] [6] An RCT of a fourth CETP inhibitor-anacetrapib-is ongoing. 7 Studies of humans with naturally occurring genetic variation in genes encoding drug targets can provide insight into the potential efficacy and safety of therapeutic modulation targeting the gene product. [8] [9] [10] Genetic studies of common, regulatory variants at the CETP gene region initially showed mixed results [11] [12] [13] [14] [15] but more recently have converged on a consensus finding: alleles with lower CETP expression are associated with reduced CHD risk. 16 Beyond common DNA sequence variants, rare mutations that truncate a therapeutic target gene may be of particular value because they most closely mirror pharmacological inhibition. 8, 9, 17 Protein-truncating variants (PTVs; ie, nonsense, canonical splice site, and frameshift mutations) at 2 therapeutic targets-NPC1L1 (NPC1-like intracellular cholesterol transporter 1) 9 and proprotein convertase subtilisin/kexin type 9 (PCSK9) 8 -are associated with lower low-density lipoprotein cholesterol (LDL-C) and reduced CHD risk. A therapeutic trial testing NPC1L1 inhibition was consistent with the human genetic findings, 18 and a trial testing PCSK9 inhibition was consistent as well. 19 Here, we tested whether rare PTVs at the CETP gene were associated with plasma lipids and reduced odds of CHD.
Methods
Study Participants
First, we sequenced a total of 58 469 participants from the MIGen consortium (Myocardial Infarction Genetics) of African, European, and South Asian ancestries (n=25 273), the DiscovEHR (DiscovEHR project of the Regeneron Genetics Center and the Geisinger Health System) of European ancestry (n=24 138), 20 and Taiwanese-Chinese (TAICHI) consortium of East Asian ancestry (n=9058) 21 ( Table 1 ). The MIGen consortium consists of the Italian ATVB study (Atherosclerosis Thrombosis and Vascular Biology), 22 the DHM study (Deutsches Herzzentrum München Myocardial Infarction), 9 the ESP-EOMI study (Exome Sequencing Project Early-Onset Myocardial Infarction) 23, 24 of European and African ancestries, the JHS (Jackson Heart Study), 25 the Leicester (Leicester Acute Myocardial Infarction Peptide Study), 26 the Lubeck (Lübeck Myocardial Infarction Study), 27 the OHS (Ottawa Heart Study), 28 the PROCARDIS (Precocious Coronary Artery Disease Study), 29 the PROMIS (Pakistan Risk of Myocardial Infarction Study), 30 and the REGICOR (Registre Gironi del COR) study. 31 We also genotyped a Japanese-specific PTV at the CETP gene (rs5742907; IVS14+1G>A; splice-donor variant 32 ) in a total of 27 561 Japanese participants from BioBank Japan (BBJ) 33 and the CAGE-CAD (Cardio-metabolic Genome Epidemiology Network and Coronary Artery Disease) stage 1 and stage 2 studies (Table 1) . 34 All participants in the study provided written informed consent for genetic studies. The Institutional Review Boards at the Broad Institute and each participating institution approved the study protocol.
Definition of CETP PTVs
PTVs were defined as premature stop (nonsense), canonical splice sites (splice donor or splice acceptor), including IVS14+1G>A (rs5742907), or insertion/deletion variants that shifted frame (frameshift). The positions of these PTVs were based on the GRGh37 human genome reference and the canonical transcript for CETP (transcript ID: ENST00000200676).
Clinical Characteristics, Lipid Measurements, and Definition of CHD
A medical history and laboratory data for cardiovascular risk factors were obtained from all the study participants. Plasma total cholesterol,
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proprotein convertase subtilisin/kexin type 9 PTV protein-truncating variant RCT randomized controlled trial triglycerides, and high-density lipoprotein cholesterol (HDL-C) levels were determined enzymatically. LDL-C level was calculated using the Friedewald equation 35, 36 for those with triglycerides <400 mg/dL. If triglycerides ≥400 mg/dL, LDL-C level was directly measured or set to missing. The effect of lipid-lowering therapy at the time of lipid measurement was taken into account by dividing the measured total cholesterol and LDL-C levels by 0.8 and 0.7, respectively.
37 HDL-C and triglyceride levels were not adjusted by lipid-altering medication use, and triglyceride levels were natural logarithm transformed for statistical analysis. CHD case and CHD-free control definitions of each study are in Online Table I .
Sequencing and Genotyping to Characterize PTVs
Whole-exome sequencing of the MIGen consortium was performed at the Broad Institute (Cambridge, MA) as previously described. 23 Sequencing reads were aligned to a human reference genome (build 37) using the Burrows-Wheeler Aligner-maximal exact match algorithm. Aligned nonduplicate reads were locally realigned, and base qualities were recalibrated using the Genome Analysis ToolKit software. 38 Variants were jointly called using the Genome Analysis ToolKit HaplotypeCaller program. The sensitivity of the Variant Quality Score Recalibration threshold was 99.6% for single nucleotide variants and 95% for insertion/deletion variants. All identified variants were annotated with the use of the Variant Effect Predictor software (version 82). 39 The DiscovEHR project and TAICHI consortium participants were exome sequenced as previously described. 20 We also genotyped 1 splice-donor variant (IVS14+1G>A [rs5742907]) at the CETP gene using the multiplex polymerase chain reaction-based target sequencing in BBJ 40 or the TaqMan assay in CAGE-CAD stage 1 and stage 2.
Statistical Analysis
We tested the association of CETP PTV carrier status with lipid levels using linear regression adjusted by age, sex, study, and the first 5 principal components of ancestry (MIGen), or by age and sex (BBJ and CAGE-CAD stage 1). Only CHD-free controls in each study were included in this assessment to minimize the effect of ascertainment bias. These data were meta-analyzed to calculate overall summary effect sizes with an inverse-variance weighted fixed-effects model.
We tested the association of CETP PTV carrier status with CHD risk using a Cochran-Mantel-Haenszel method without continuous correction. This method combines score statistics instead of Wald statistics and is useful for rare exposures when some observed odds ratios are zero. We removed ESP-EOMI and JHS from this analysis because no participant in these 2 studies carried a PTV at the CETP gene.
In an exploratory analysis, we evaluated whether the effect of CETP PTVs on LDL-C could explain the reduction in CHD risk. We used an inverse-variance weighted model to draw a regression line with a 95% confidence interval (CI). Across 4 genes (APOB, NPC1L1, PCSK9, and CETP), we plotted the effect of DNA sequence variants in these genes on both LDL-C and CHD risk. The results for APOB, NPC1L1, and PCSK9 are derived from samples of the MIGen (24) 5069 (20) 5 (31) 4126 (17) 8 (44) 4343 (48) 78 (64) 8568 (55) 9 (42) 917 (35) 16 (21) 2174 (23) Lipid-lowering medication,* n (%)
1 (3) 3682 (15) 4 (25) 6129 (25) 3 (19) 1781 (22) 43 (35) 5164 (33) (24) 41 (14) 58 (14) 51 (15) 58 (23) 45 (14) 67 (25) 50 (15) 78 (24) 58 ( consortium to draw a dose-response reference line. The results for CETP are summary estimate from all studies. Statistical analyses were performed using R software version 3.2.3 (The R Project for Statistical Computing, Vienna, Austria).
Results
Prevalence of CETP PTVs
Sequencing of the 16 exons at the CETP gene was performed in 58 469 participants (18 817 CHD cases and 39 652 CHDfree controls) from 3 projects: the MIGen consortium, the DiscovEHR project, and TAICHI consortium. Baseline characteristics of each study are shown in Table 1 . A total of 23 PTVs were identified (10 premature stop, 9 frameshifts, 3 splice-donor variants, and 1 splice-accepter variant). A total of 60 individuals carried one of the CETP PTVs, including 18 CHD cases (0.096%; 95% CI, 0.051%-0.14%) and 42 CHDfree controls (0.11%; 95% CI, 0.074%-0.14%). Baseline characteristics by variant carrier status are shown in Online  Table II . We genotyped a Japanese-specific splice-donor variant (IVS14+1G>A [rs5742907]) in 3 studies from Japan and found the carrier frequency to be BBJ, 0.78%; CAGE-CAD stage 1, 0.81%; and CAGE-CAD stage 2, 0.92%.
Association of CETP PTVs With Plasma Lipids
We assessed whether CETP PTV carrier status was associated with lipid levels (Table 2; Online Figure) . We obtained plasma lipid profiles in 11 205 control participants from the MIGen consortium and 6955 control participants from BBJ and CAGE-CAD stage 1. CETP PTV carrier status was associated with increased HDL-C (effect size, 22.6 mg/dL; 95% CI, 18-27; P<1×10 
Association of CETP PTVs With CHD
We evaluated the association of CETP PTV carrier status with CHD. Baseline characteristics and lists of CETP PTVs by case-control status in each study are shown in Online Table III  and Online Table IV . In an analysis including a total of 82 722 participants, CETP PTV carrier status was significantly associated with lower risk for CHD (summary odds ratio, 0.70; 95% CI, 0.54-0.90; P=5.1×10 −3 ; Figure 1 ).
DNA Sequence Variants, LDL-C, and CHD Risk Across 4 Genes
We explored whether the effect size of CETP PTV on CHD risk was consistent with its effect on LDL-C. We drew a dose-response reference line for CHD risk as a function of LDL-C change conferred by DNA sequence variants in 3 genes other than CETP. DNA sequence variants in APOB, NPC1L1, and PCSK9 associated with lower LDL-C also correlated with lower CHD risk. The effect of CETP PTV on CHD risk (30% reduction in risk) was consistent with the estimate based on the change in LDL-C (−12.2 mg/dL; Figure 2 ).
Discussion
Across >80 000 participants, we evaluated whether CETP PTVs were associated with lipid levels and risk for CHD. About 1 in 975 participants carried a PTV at the CETP gene in sequencing studies, and compared with noncarriers, CETP PTV carriers exhibited significantly higher plasma HDL-C levels and lower LDL-C and triglyceride levels. The presence of a CETP PTV was also associated with decreased risk for CHD. This evidence from rare human mutations that disrupt the CETP gene is consistent with earlier data on common, regulatory variants at the CETP locus. Common variants in CETP have been associated with increased HDL-C, decreased LDL-C, decreased triglyceride levels, 41 and reduced risk for CHD. 13, [42] [43] [44] And recently, the statistical evidence for association of common CETP variants with CHD has exceeded a stringent genome-wide threshold. 16 Exploratory analyses suggest that the effect of CETP PTV on lower CHD risk is consistent with lower LDL-C change conferred by these variants.
If human genetics shows loss of CETP function mutations to be associated with reduced CHD risk, why have 3 small molecule inhibitors of CETP function all failed to show lower CHD outcomes in randomized clinical trials? Several possibilities emerge. First, this could be because of off-target adverse effects of small molecule inhibitors. Torcetrapib, dalcetrapib, and evacetrapib treatment all led to higher blood pressure in RCTs [1] [2] [3] ; torcetrapib also led to hyperaldosteronism. 1 Second, RCT design factors, such as limited statistical power, could play a role. 4, 5 Human genetic evidence is supportive for apolipoprotein B-containing lipoproteins (low-density lipoprotein, triglyceride-rich lipoproteins, lipoprotein[a]) as causal factors for CHD, whereas this is not the case for HDL-C. 6 As such, any benefit from CETP inhibition may be solely because of the lowering of apolipoprotein B-containing lipoproteins. On background statin therapy, the LDL cholesterol and apolipoprotein B-lowering effect are smaller, as shown in the ACCELERATE trial As such, it is unclear whether RCTs were adequately powered to detect this benefit.
Third, statin therapy may modify the relationship of CETP activity and coronary disease. CETP promotes the transfer of cholesteryl esters from HDL to atherogenic apolipoprotein B-containing lipoproteins, including LDL. 4 If not cleared from the circulation, accumulation of such particles in the bloodstream promotes atherosclerotic progression. However, statins lead to substantial upregulation of hepatic LDL receptor density. 45 In this context, apolipoprotein B-containing lipoproteins may be rapidly cleared from the circulation and excreted into the feces. CETP may, therefore, play a role in promoting reverse cholesterol transport, the process by which cholesterol is extracted from peripheral tissues (eg, atherosclerotic plaque) and excreted from the body. Overexpression of CETP leads to enhanced reverse cholesterol transport via an LDL receptor-dependent pathway in mouse models. 46 Furthermore, individuals with increased on-statin CETP mass were protected from recurrent coronary events, particularly when the achieved LDL cholesterol was <80 mg/dL. 47 Under this framework, pharmacological CETP inhibition might prove less effective or potentially harmful among those in whom statin therapy leads to efficient clearance of apolipoprotein B-containing lipoproteins. However, the impact of CETP inhibition on reverse cholesterol transport has been questioned because the mouse studies might have been confounded by cholesterol pool size changes. 48 Also, torcetrapib did not elevate fecal cholesterols or bile acids in both on-and off-statin individuals. 49 Fourth, a major difference in individuals with heterozygous PTV mutations in CETP and individuals taking the CETP inhibitors is the accumulation of a cholesteryl ester-rich HDL in the latter, which may be a toxic lipoprotein particle like cholesteryl ester-rich LDL.
Finally, phenotypic consequences of human PTVs reflect lifelong perturbation of a gene in every human tissue. In contrast, the results of RCTs reflect pharmacological inhibition initiated later in life. As such, there are intrinsic limitations in using human mutations to anticipate efficacy and safety of pharmacological manipulation.
These results should be interpreted in the context of study limitations. Definitions of CHD were different among studies. Cases in the MIGen consortium and the DiscovEHR project were limited to only early-onset CHD, whereas those in East Asian studies were not. Loss of CETP function alters the distribution of cholesterol and triglycerides in lipoproteins, and as such, LDL-C levels estimated by the Friedewald equation might overestimate the reduction in participants harboring CETP PTVs. We only assessed 4 major lipid levels to evaluate effects of CETP PTV carrier status, and other traits such as lipoprotein (a) or function of reverse cholesterol transport were unavailable. Results were somewhat stronger in participants from the Japanese genotyping studies, but the point estimates of the odds ratios for CHD were consistent between populations of Japanese and non-Japanese ancestries (0.69 and 0.73, respectively).
Conclusions
In this meta analyses of data from 15 case-control studies, rare PTVs at the CETP gene were associated with higher HDL-C, lower LDL-C, lower triglycerides, and reduced risk for CHD.
